loading

Dechra Pharmaceuticals PLC Dechra Pharmaceuticals PLC
  • Strategic Report
    • Welcome to Dechra Pharmaceuticals PLC
    • Highlights
    • Group at a Glance
    • Chairman's and Chief Executive Officer's Statement
    • Delivering Our Strategy
    • Strategy in Action
    • Q&A with Ian Page
    • Our Business Model
    • Creating Value
    • Our Marketplace
    • Our Key Products
    • International Footprint
    • Product Development
    • Financial Review
    • Key Performance Indicators
    • Corporate Social Responsibility
    • How the Business Manages Risk
    • Understanding Our Key Risks
  • Our Governance
    • Board of Directors
    • Letter from the Chairman on Governance
    • Corporate Governance
    • Letter from the Audit Committee Chairman
    • Audit Committee Report
    • Nomination Committee Report
    • Letter from the Remuneration Committee Chairman
    • Directors' Remuneration Report
    • Directors' Report - Other Disclosures
    • Statement of Directors' Responsibilities
  • Our Financials
    • Independent Auditor's Report to the Members of Dechra Pharmaceuticals PLC
    • Consolidated Income Statement
    • Consolidated Statement of Comprehensive Income
    • Consolidated Statement of Financial Position
    • Consolidated Statement of Changes in Shareholders' Equity
    • Consolidated Statement of Cash Flows
    • Notes to the Consolidated Financial Statements
    • Company Statement of Financial Position
    • Statement of Changes in Shareholders' Equity
    • Notes to the Company Financial Statements
    • Financial History
  • Company Information
    • Glossary
    • Shareholder Information
    • Advisers
  • Home
  • Our Financials
  • Notes to the Company Financial Statements

Annual Report & Accounts for the year ended 30 June 2016

  • Page Previous Navigation Page Previous Navigation
  • Page Next Navigation Page Next Navigation

Notes to the Company Financial Statements

  • (i) Principal Accounting Policies of the Company
  • (ii) Directors and Employees
  • (iii) Investments
  • (iv) Intangible Assets
  • (v) Tangible Assets
  • (vi) Trade and Other Receivables
  • (vii) Trade and Other Payables
  • (viii) Borrowings
  • (ix) Deferred Tax
  • (x) Called up Share Capital
  • (xi) Reconciliation of Total Equity as at 1 July 2014 and 30 June 2015
  • (xii) Subsidiary Undertakings
  • Page Previous Navigation Page Previous Navigation prev Statement of Changes in Shareholders' Equity
  • Page Next Navigation Page Next Navigation next (i) Principal Accounting Policies of the Company

Site Essentials

  • Site Map
  • Accessibility
  • Cookies
  • Downloads

© 2016 Dechra Pharmaceuticals PLC

Top

Powered By Jones and Palmer